Lars Jørgen Østergaard

Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. / Reekie, Joanne; Kosa, Csaba; Engsig, Frederik; Monforte, Antonella d'Arminio; Wiercinska-Drapalo, Alicja; Domingo, Pere; Antunes, Francisco; Clumeck, Nathan; Kirk, Ole; Lundgren, Jens D; Mocroft, Amanda; EuroSIDA Study Group (Lars Østergaard, member).

In: Cancer, Vol. 116, No. 22, 15.11.2010, p. 5306-15.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Reekie, J, Kosa, C, Engsig, F, Monforte, ADA, Wiercinska-Drapalo, A, Domingo, P, Antunes, F, Clumeck, N, Kirk, O, Lundgren, JD, Mocroft, A & EuroSIDA Study Group (Lars Østergaard, member) 2010, 'Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies', Cancer, vol. 116, no. 22, pp. 5306-15. https://doi.org/10.1002/cncr.25311

APA

Reekie, J., Kosa, C., Engsig, F., Monforte, A. DA., Wiercinska-Drapalo, A., Domingo, P., Antunes, F., Clumeck, N., Kirk, O., Lundgren, J. D., Mocroft, A., & EuroSIDA Study Group (Lars Østergaard, member) (2010). Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer, 116(22), 5306-15. https://doi.org/10.1002/cncr.25311

CBE

Reekie J, Kosa C, Engsig F, Monforte ADA, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A, EuroSIDA Study Group (Lars Østergaard, member). 2010. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 116(22):5306-15. https://doi.org/10.1002/cncr.25311

MLA

Vancouver

Reekie J, Kosa C, Engsig F, Monforte ADA, Wiercinska-Drapalo A, Domingo P et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010 Nov 15;116(22):5306-15. https://doi.org/10.1002/cncr.25311

Author

Reekie, Joanne ; Kosa, Csaba ; Engsig, Frederik ; Monforte, Antonella d'Arminio ; Wiercinska-Drapalo, Alicja ; Domingo, Pere ; Antunes, Francisco ; Clumeck, Nathan ; Kirk, Ole ; Lundgren, Jens D ; Mocroft, Amanda ; EuroSIDA Study Group (Lars Østergaard, member). / Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. In: Cancer. 2010 ; Vol. 116, No. 22. pp. 5306-15.

Bibtex

@article{f2ec0226eb044249ab9de127c660f98e,
title = "Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies",
abstract = "BACKGROUND: In the combined antiretroviral therapy (cART) era, non-acquired immunodeficiency syndrome (AIDS)-defining malignancies account for more morbidity and mortality in human immunodeficiency virus-infected patients than AIDS-defining malignancies. However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies.METHODS: A total of 14,453 patients from the prospective, multinational EuroSIDA cohort were included. Malignancies were classified as virus-related, non-virus-related epithelial, and other. The incidence of non-AIDS-defining malignancies was calculated stratified by current CD4 count. Poisson regression was used to investigate factors associated with the development of non-AIDS-defining malignancies.RESULTS: A total of 356 non-AIDS-defining malignancies occurred, with an incidence rate of 4.3 per 1000 person years of follow-up (95% confidence interval [CI], 3.8-4.7); 172 (48.3%) were virus-related, 135 (37.9%) were non-virus-related epithelial, and 49 (13.7%) were classified as other. Anal (69 cases), lung (31 cases), and melanoma (13 cases), respectively, were the most common non-AIDS-defining malignancies within each group. After adjustment, current CD4 was associated with virus-related non-AIDS-defining malignancies (incidence rate ratio [IRR], 0.81 per doubling; 95% CI, 0.75-0.88; P < .0001) and non-virus-related epithelial non-AIDS-defining malignancies (IRR, 0.84; 95% CI, 0.75-0.95; P = .004), but not with other non-AIDS-defining malignancies (IRR, 1.04; 95% CI, 0.83-1.31; P = .73). Current CD4 count was also associated with anal cancer (IRR, 0.86; 95% CI, 0.75-0.99; P = .03), Hodgkin lymphoma (n = 52; IRR, 0.83; 95% CI, 0.73-0.95; P = .005), and lung cancer (IRR, 0.76; 95% CI, 0.64-0.90; P = .0002).CONCLUSIONS: A low current CD4 count was associated with an increased incidence of certain non-AIDS-defining malignancies. Starting cART earlier to reduce the proportion of patients with a low CD4 count may decrease the rate of developing many common non-AIDS-related malignancies. A randomized trial to explore this strategy is urgently needed.",
keywords = "Acquired Immunodeficiency Syndrome, Adult, CD4 Lymphocyte Count, Female, Humans, Incidence, Male, Neoplasms, Risk Factors, Tumor Virus Infections",
author = "Joanne Reekie and Csaba Kosa and Frederik Engsig and Monforte, {Antonella d'Arminio} and Alicja Wiercinska-Drapalo and Pere Domingo and Francisco Antunes and Nathan Clumeck and Ole Kirk and Lundgren, {Jens D} and Amanda Mocroft and {EuroSIDA Study Group (Lars {\O}stergaard, member)} and {\O}stergaard, {Lars J{\o}rgen}",
note = "Copyright {\textcopyright} 2010 American Cancer Society.",
year = "2010",
month = nov,
day = "15",
doi = "10.1002/cncr.25311",
language = "English",
volume = "116",
pages = "5306--15",
journal = "Cancer",
issn = "0008-543X",
publisher = "JohnWiley & Sons, Inc.",
number = "22",

}

RIS

TY - JOUR

T1 - Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

AU - Reekie, Joanne

AU - Kosa, Csaba

AU - Engsig, Frederik

AU - Monforte, Antonella d'Arminio

AU - Wiercinska-Drapalo, Alicja

AU - Domingo, Pere

AU - Antunes, Francisco

AU - Clumeck, Nathan

AU - Kirk, Ole

AU - Lundgren, Jens D

AU - Mocroft, Amanda

AU - EuroSIDA Study Group (Lars Østergaard, member)

A2 - Østergaard, Lars Jørgen

N1 - Copyright © 2010 American Cancer Society.

PY - 2010/11/15

Y1 - 2010/11/15

N2 - BACKGROUND: In the combined antiretroviral therapy (cART) era, non-acquired immunodeficiency syndrome (AIDS)-defining malignancies account for more morbidity and mortality in human immunodeficiency virus-infected patients than AIDS-defining malignancies. However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies.METHODS: A total of 14,453 patients from the prospective, multinational EuroSIDA cohort were included. Malignancies were classified as virus-related, non-virus-related epithelial, and other. The incidence of non-AIDS-defining malignancies was calculated stratified by current CD4 count. Poisson regression was used to investigate factors associated with the development of non-AIDS-defining malignancies.RESULTS: A total of 356 non-AIDS-defining malignancies occurred, with an incidence rate of 4.3 per 1000 person years of follow-up (95% confidence interval [CI], 3.8-4.7); 172 (48.3%) were virus-related, 135 (37.9%) were non-virus-related epithelial, and 49 (13.7%) were classified as other. Anal (69 cases), lung (31 cases), and melanoma (13 cases), respectively, were the most common non-AIDS-defining malignancies within each group. After adjustment, current CD4 was associated with virus-related non-AIDS-defining malignancies (incidence rate ratio [IRR], 0.81 per doubling; 95% CI, 0.75-0.88; P < .0001) and non-virus-related epithelial non-AIDS-defining malignancies (IRR, 0.84; 95% CI, 0.75-0.95; P = .004), but not with other non-AIDS-defining malignancies (IRR, 1.04; 95% CI, 0.83-1.31; P = .73). Current CD4 count was also associated with anal cancer (IRR, 0.86; 95% CI, 0.75-0.99; P = .03), Hodgkin lymphoma (n = 52; IRR, 0.83; 95% CI, 0.73-0.95; P = .005), and lung cancer (IRR, 0.76; 95% CI, 0.64-0.90; P = .0002).CONCLUSIONS: A low current CD4 count was associated with an increased incidence of certain non-AIDS-defining malignancies. Starting cART earlier to reduce the proportion of patients with a low CD4 count may decrease the rate of developing many common non-AIDS-related malignancies. A randomized trial to explore this strategy is urgently needed.

AB - BACKGROUND: In the combined antiretroviral therapy (cART) era, non-acquired immunodeficiency syndrome (AIDS)-defining malignancies account for more morbidity and mortality in human immunodeficiency virus-infected patients than AIDS-defining malignancies. However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies.METHODS: A total of 14,453 patients from the prospective, multinational EuroSIDA cohort were included. Malignancies were classified as virus-related, non-virus-related epithelial, and other. The incidence of non-AIDS-defining malignancies was calculated stratified by current CD4 count. Poisson regression was used to investigate factors associated with the development of non-AIDS-defining malignancies.RESULTS: A total of 356 non-AIDS-defining malignancies occurred, with an incidence rate of 4.3 per 1000 person years of follow-up (95% confidence interval [CI], 3.8-4.7); 172 (48.3%) were virus-related, 135 (37.9%) were non-virus-related epithelial, and 49 (13.7%) were classified as other. Anal (69 cases), lung (31 cases), and melanoma (13 cases), respectively, were the most common non-AIDS-defining malignancies within each group. After adjustment, current CD4 was associated with virus-related non-AIDS-defining malignancies (incidence rate ratio [IRR], 0.81 per doubling; 95% CI, 0.75-0.88; P < .0001) and non-virus-related epithelial non-AIDS-defining malignancies (IRR, 0.84; 95% CI, 0.75-0.95; P = .004), but not with other non-AIDS-defining malignancies (IRR, 1.04; 95% CI, 0.83-1.31; P = .73). Current CD4 count was also associated with anal cancer (IRR, 0.86; 95% CI, 0.75-0.99; P = .03), Hodgkin lymphoma (n = 52; IRR, 0.83; 95% CI, 0.73-0.95; P = .005), and lung cancer (IRR, 0.76; 95% CI, 0.64-0.90; P = .0002).CONCLUSIONS: A low current CD4 count was associated with an increased incidence of certain non-AIDS-defining malignancies. Starting cART earlier to reduce the proportion of patients with a low CD4 count may decrease the rate of developing many common non-AIDS-related malignancies. A randomized trial to explore this strategy is urgently needed.

KW - Acquired Immunodeficiency Syndrome

KW - Adult

KW - CD4 Lymphocyte Count

KW - Female

KW - Humans

KW - Incidence

KW - Male

KW - Neoplasms

KW - Risk Factors

KW - Tumor Virus Infections

U2 - 10.1002/cncr.25311

DO - 10.1002/cncr.25311

M3 - Journal article

C2 - 20661911

VL - 116

SP - 5306

EP - 5315

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 22

ER -